Back to News
Market Impact: 0.25
Needham Upgrades Rocket Pharmaceuticals to Buy from Hold
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
Needham upgraded Rocket Pharmaceuticals (NASDAQGM:RCKT) to Buy from Hold on September 16, 2026. The rating change is a positive signal for the biotech company, though the article provides no price target, clinical-data update, or financial details supporting the upgrade.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
RCKT0.55
More News
- Amgen (AMGN) Bets on MariTide to Crack $120 Billion Obesity Market
- BTIG cuts Acumen Pharmaceuticals stock price target to $1 on trial results
- Wells Fargo raises Chevron stock price target on upstream strength
- All eyes on Kosmos Energy earnings after 200% stock rally
- Wells Fargo raises CBOE Holdings price target to $357 on estimates
- Wells Fargo cuts Gates Industrial stock price target on margin outlook